Immunovant, Inc.
Immunovant, Inc.（IMVT）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · IMVT · 截至 2025年3月31日
股东结构概览
214
机构持有人数
▲ 6 vs Q4
$1.62B
机构持仓总市值
▼ $364.71M vs Q4
205.31M
总流通股
freeFloat 38.40%
94.76M
13F 申报持股数
▲ 14.62M vs Q4
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
IMVT 最大股东 · 机构持仓
Q1 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
FMR LLC biological products, (no diagnostic substances) | 17.24M | 11.73% | 11.73% | $294.65B | May 12, 2025 | ▲ 4.14M |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 9.50M | 6.47% | 6.47% | $162.35B | May 15, 2025 | ▲ 3.50M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 6.94M | 4.72% | 4.72% | $118.55B | May 9, 2025 | ▲ 257.4K |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 5.89M | 4.01% | 4.01% | $100.74B | May 14, 2025 | ▲ 777.6K |
BAKER BROS. ADVISORS LP biological products, (no diagnostic substances) | 5.46M | 3.71% | 3.71% | $93.28B | May 15, 2025 | ▲ 3.75M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 5.36M | 3.65% | 3.65% | $91.67B | May 2, 2025 | ▲ 221.2K |
ARMISTICE CAPITAL, LLC biological products, (no diagnostic substances) | 4.50M | 3.06% | 3.06% | $76.91B | May 15, 2025 | ▲ 629.4K |
STATE STREET CORP biological products, (no diagnostic substances) | 3.09M | 2.10% | 2.10% | $52.76B | May 15, 2025 | ▲ 389.6K |
PERCEPTIVE ADVISORS LLC biological products, (no diagnostic substances) | 2.84M | 1.94% | 1.94% | $48.61B | Aug 6, 2025 | ▲ 704.9K |
ALPINE GLOBAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.63M | 1.79% | 1.79% | $44.89B | May 15, 2025 | ▲ 467.8K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q1 2025 对比上季度
Q1 2025
34
增持
+19.39M 股4
新建仓
首次建仓11
减持
−1.94M 股0
清仓
完全退出净股数变化（前50家）
+17.45M
+19.39M / −1.94M
净新增持仓人
+27
新建 4 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
IMVT 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
28
买入笔数
22
卖出笔数
1.27
买卖比
$1M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Fromkin Andrew J. director | May 28, 2026 | Sale | 11,483 | $32.64 | $374.8K | 284.9K | Form 4 ↗ |
Fromkin Andrew J. director | May 28, 2026 | Sale | 210,468 | $33.56 | $7.06M | 74.4K | Form 4 ↗ |
Gloria Melanie Chief Operating Officer | May 20, 2026 | Sale | 249 | $30.41 | $7.6K | 245.0K | Form 4 ↗ |
Gloria Melanie Chief Operating Officer | May 20, 2026 | Sale | 1,168 | $32.15 | $37.6K | 243.8K | Form 4 ↗ |
Gloria Melanie Chief Operating Officer | May 20, 2026 | Sale | 1,698 | $32.95 | $55.9K | 242.1K | Form 4 ↗ |
Pande Atul director | May 20, 2026 | Sale | 6,000 | $32.00 | $192.0K | 116.7K | Form 4 ↗ |
Susman Robert Graham director | May 1, 2026 | Sale | 2,502 | $27.17 | $68.0K | 36.4K | Form 4 ↗ |
Girao Tiago Chief Financial Officer | Apr 23, 2026 | Sale | 25,760 | $29.62 | $763.0K | 247.6K | Form 4 ↗ |
Stout Jay S Chief Technology Officer | Apr 23, 2026 | Sale | 2,754 | $29.62 | $81.6K | 251.7K | Form 4 ↗ |
Van Tuyl Christopher Chief Legal Officer | Apr 8, 2026 | Sale | 5,165 | $24.83 | $128.2K | 183.2K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Immunovant, Inc.（IMVT）主要由机构投资者持有，机构持股比例约为 46.1%。公司内部人员持股约 61.60%，散户及公众持股约占剩余的 0.00%。
Immunovant, Inc. 最大机构股东为 FMR LLC，截至 March 31, 2025 持有约 17.24 million 股，占总流通股的 11.73%。
目前共有 214 家机构持有 IMVT 股票，合计持仓市值约 $1.62 billion，数据来源为最新 SEC 13F 申报。
常见问题
IMVT ownershipImmunovant, Inc.（IMVT）主要由机构投资者持有，机构持股约 46.1%。最大股东为 FMR LLC，持股比例 11.73%。内部人员持股约 61.60%。数据来源 SEC Form 13F，截至 March 31, 2025。